Skip to main content
Top
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | Hepatitis | Comment

A dual role for adeno-associated virus in human health

Author: Natalia M Araujo

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Adeno-associated virus (AAV) differs from most other viruses, as it requires the simultaneous presence of a helper virus for an active infection. Up to 80% of the human population is seropositive for AAV antibodies. AAV has been known to be a non-pathogenic virus and an inhibitor of carcinogenesis caused by coinfecting viruses. However, the recent reports associating AAV infection with hepatocellular carcinoma development and the mysterious cases of acute severe hepatitis in children have challenged the idea that AAV is a harmless virus. Herein, we explore the usefulness of AAV in gene therapy and the importance of AAV as a protector or perpetrator in human carcinogenesis, ultimately reflecting on the dual role of AAV in human health.
Literature
1.
go back to reference Atchison RW, Casto BC, Hammon WM. Adenovirus-Associated defective virus particles. Science. 1965;149:754–6.CrossRefPubMed Atchison RW, Casto BC, Hammon WM. Adenovirus-Associated defective virus particles. Science. 1965;149:754–6.CrossRefPubMed
2.
go back to reference Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199:381–90.CrossRefPubMed Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199:381–90.CrossRefPubMed
3.
go back to reference Kruzik A, Fetahagic D, Hartlieb B, Dorn S, Koppensteiner H, Horling FM, Scheiflinger F, Reipert BM, de la Rosa M. Prevalence of Anti-Adeno-Associated Virus Immune responses in international cohorts of healthy donors. Mol Ther Methods Clin Dev. 2019;14:126–33.CrossRefPubMedPubMedCentral Kruzik A, Fetahagic D, Hartlieb B, Dorn S, Koppensteiner H, Horling FM, Scheiflinger F, Reipert BM, de la Rosa M. Prevalence of Anti-Adeno-Associated Virus Immune responses in international cohorts of healthy donors. Mol Ther Methods Clin Dev. 2019;14:126–33.CrossRefPubMedPubMedCentral
4.
go back to reference Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004;78:6381–8.CrossRefPubMedPubMedCentral Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004;78:6381–8.CrossRefPubMedPubMedCentral
5.
go back to reference Meier AF, Fraefel C, Seyffert M. The interplay between Adeno-Associated Virus and its helper viruses. Viruses 2020, 12. Meier AF, Fraefel C, Seyffert M. The interplay between Adeno-Associated Virus and its helper viruses. Viruses 2020, 12.
6.
go back to reference Hastie E, Samulski RJ. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success–a personal perspective. Hum Gene Ther. 2015;26:257–65.CrossRefPubMedPubMedCentral Hastie E, Samulski RJ. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success–a personal perspective. Hum Gene Ther. 2015;26:257–65.CrossRefPubMedPubMedCentral
7.
go back to reference Luo J, Luo Y, Sun J, Zhou Y, Zhang Y, Yang X. Adeno-associated virus-mediated cancer gene therapy: current status. Cancer Lett. 2015;356:347–56.CrossRefPubMed Luo J, Luo Y, Sun J, Zhou Y, Zhang Y, Yang X. Adeno-associated virus-mediated cancer gene therapy: current status. Cancer Lett. 2015;356:347–56.CrossRefPubMed
9.
go back to reference Issa SS, Shaimardanova AA, Solovyeva VV, Rizvanov AA. Various AAV serotypes and their applications in Gene Therapy: an overview. Cells 2023, 12. Issa SS, Shaimardanova AA, Solovyeva VV, Rizvanov AA. Various AAV serotypes and their applications in Gene Therapy: an overview. Cells 2023, 12.
10.
go back to reference Keam SJ. Eladocagene Exuparvovec: first approval. Drugs. 2022;82:1427–32.PubMed Keam SJ. Eladocagene Exuparvovec: first approval. Drugs. 2022;82:1427–32.PubMed
12.
go back to reference Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature. 2001;412:914–7.CrossRefPubMed Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature. 2001;412:914–7.CrossRefPubMed
13.
go back to reference Hermonat PL. Adeno-associated virus inhibits human papillomavirus type 16: a viral interaction implicated in cervical cancer. Cancer Res. 1994;54:2278–81.PubMed Hermonat PL. Adeno-associated virus inhibits human papillomavirus type 16: a viral interaction implicated in cervical cancer. Cancer Res. 1994;54:2278–81.PubMed
14.
go back to reference Hermonat PL, Plott RT, Santin AD, Parham GP, Flick JT. Adeno-associated virus Rep78 inhibits oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric. Gynecol Oncol. 1997;66:487–94.CrossRefPubMed Hermonat PL, Plott RT, Santin AD, Parham GP, Flick JT. Adeno-associated virus Rep78 inhibits oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric. Gynecol Oncol. 1997;66:487–94.CrossRefPubMed
15.
go back to reference Walz CM, Correa-Ochoa MM, Muller M, Schlehofer JR. Adenoassociated virus type 2-induced inhibition of the human papillomavirus type 18 promoter in transgenic mice. Virology. 2002;293:172–81.CrossRefPubMed Walz CM, Correa-Ochoa MM, Muller M, Schlehofer JR. Adenoassociated virus type 2-induced inhibition of the human papillomavirus type 18 promoter in transgenic mice. Virology. 2002;293:172–81.CrossRefPubMed
16.
go back to reference Coker AL, Russell RB, Bond SM, Pirisi L, Liu Y, Mane M, Kokorina N, Gerasimova T, Hermonat PL. Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia. Exp Mol Pathol. 2001;70:83–9.CrossRefPubMed Coker AL, Russell RB, Bond SM, Pirisi L, Liu Y, Mane M, Kokorina N, Gerasimova T, Hermonat PL. Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia. Exp Mol Pathol. 2001;70:83–9.CrossRefPubMed
17.
go back to reference Freitas LB, Tonani de Mattos A, Lima BM, Miranda AE, Spano LC. Adeno-associated virus may play a protective role against human papillomavirus-induced cervical lesions independent of HIV serostatus. Int J STD AIDS. 2012;23:258–61.CrossRefPubMed Freitas LB, Tonani de Mattos A, Lima BM, Miranda AE, Spano LC. Adeno-associated virus may play a protective role against human papillomavirus-induced cervical lesions independent of HIV serostatus. Int J STD AIDS. 2012;23:258–61.CrossRefPubMed
18.
go back to reference Georg-Fries B, Biederlack S, Wolf J, zur Hausen H. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology. 1984;134:64–71.CrossRefPubMed Georg-Fries B, Biederlack S, Wolf J, zur Hausen H. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology. 1984;134:64–71.CrossRefPubMed
19.
go back to reference La Bella T, Imbeaud S, Peneau C, Mami I, Datta S, Bayard Q, Caruso S, Hirsch TZ, Calderaro J, Morcrette G, et al. Adeno-associated virus in the liver: natural history and consequences in tumour development. Gut. 2020;69:737–47.CrossRefPubMed La Bella T, Imbeaud S, Peneau C, Mami I, Datta S, Bayard Q, Caruso S, Hirsch TZ, Calderaro J, Morcrette G, et al. Adeno-associated virus in the liver: natural history and consequences in tumour development. Gut. 2020;69:737–47.CrossRefPubMed
20.
go back to reference Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouze E, Pilati C, Verret B, Blanc JF, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015;47:1187–93.CrossRefPubMed Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouze E, Pilati C, Verret B, Blanc JF, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015;47:1187–93.CrossRefPubMed
21.
go back to reference Tatsuno K, Midorikawa Y, Takayama T, Yamamoto S, Nagae G, Moriyama M, Nakagawa H, Koike K, Moriya K, Aburatani H. Impact of AAV2 and Hepatitis B Virus Integration into Genome on Development of Hepatocellular Carcinoma in patients with prior Hepatitis B Virus infection. Clin Cancer Res. 2019;25:6217–27.CrossRefPubMed Tatsuno K, Midorikawa Y, Takayama T, Yamamoto S, Nagae G, Moriyama M, Nakagawa H, Koike K, Moriya K, Aburatani H. Impact of AAV2 and Hepatitis B Virus Integration into Genome on Development of Hepatocellular Carcinoma in patients with prior Hepatitis B Virus infection. Clin Cancer Res. 2019;25:6217–27.CrossRefPubMed
22.
go back to reference Chandler RJ, LaFave MC, Varshney GK, Trivedi NS, Carrillo-Carrasco N, Senac JS, Wu W, Hoffmann V, Elkahloun AG, Burgess SM, Venditti CP. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. 2015;125:870–80.CrossRefPubMedPubMedCentral Chandler RJ, LaFave MC, Varshney GK, Trivedi NS, Carrillo-Carrasco N, Senac JS, Wu W, Hoffmann V, Elkahloun AG, Burgess SM, Venditti CP. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. 2015;125:870–80.CrossRefPubMedPubMedCentral
23.
go back to reference Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, Sands MS. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007;317:477.CrossRefPubMed Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, Sands MS. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007;317:477.CrossRefPubMed
24.
go back to reference Sabatino DE, Bushman FD, Chandler RJ, Crystal RG, Davidson BL, Dolmetsch R, Eggan KC, Gao G, Gil-Farina I, Kay MA, et al. Evaluating the state of the science for adeno-associated virus integration: an integrated perspective. Mol Ther. 2022;30:2646–63.CrossRefPubMedPubMedCentral Sabatino DE, Bushman FD, Chandler RJ, Crystal RG, Davidson BL, Dolmetsch R, Eggan KC, Gao G, Gil-Farina I, Kay MA, et al. Evaluating the state of the science for adeno-associated virus integration: an integrated perspective. Mol Ther. 2022;30:2646–63.CrossRefPubMedPubMedCentral
25.
go back to reference Ho A, Orton R, Tayler R, Asamaphan P, Herder V, Davis C, Tong L, Smollett K, Manali M, Allan J et al. Adeno-associated virus 2 infection in children with non-A-E hepatitis. Nature 2023. Ho A, Orton R, Tayler R, Asamaphan P, Herder V, Davis C, Tong L, Smollett K, Manali M, Allan J et al. Adeno-associated virus 2 infection in children with non-A-E hepatitis. Nature 2023.
26.
go back to reference Morfopoulou S, Buddle S, Montaguth OET, Atkinson L, Guerra-Assuncao JA, Marjaneh MM, Chiozzi RZ, Storey N, Campos L, Hutchinson JC et al. Genomic investigations of unexplained acute hepatitis in children. Nature 2023. Morfopoulou S, Buddle S, Montaguth OET, Atkinson L, Guerra-Assuncao JA, Marjaneh MM, Chiozzi RZ, Storey N, Campos L, Hutchinson JC et al. Genomic investigations of unexplained acute hepatitis in children. Nature 2023.
27.
go back to reference Servellita V, Gonzalez AS, Lamson DM, Foresythe A, Huh HJ, Bazinet AL, Bergman NH, Bull RL, Garcia KY, Goodrich JS et al. Adeno-associated virus type 2 in US children with acute severe hepatitis. Nature 2023. Servellita V, Gonzalez AS, Lamson DM, Foresythe A, Huh HJ, Bazinet AL, Bergman NH, Bull RL, Garcia KY, Goodrich JS et al. Adeno-associated virus type 2 in US children with acute severe hepatitis. Nature 2023.
30.
go back to reference Lumley SF, Richens N, Lees E, Cregan J, Kalimeris E, Oakley S, Morgan M, Segal S, Dawson M, Walker AS, et al. Changes in paediatric respiratory infections at a UK teaching hospital 2016–2021; impact of the SARS-CoV-2 pandemic. J Infect. 2022;84:40–7.CrossRefPubMed Lumley SF, Richens N, Lees E, Cregan J, Kalimeris E, Oakley S, Morgan M, Segal S, Dawson M, Walker AS, et al. Changes in paediatric respiratory infections at a UK teaching hospital 2016–2021; impact of the SARS-CoV-2 pandemic. J Infect. 2022;84:40–7.CrossRefPubMed
31.
go back to reference Matthews PC, Campbell C, Sandulescu O, Maticic M, Ruta SM, Rivero-Juarez A, van Welzen BJ, Tan BK, Garcia F, Gherlan GS, et al. Acute severe hepatitis outbreak in children: a perfect storm. What do we know, and what questions remain? Front Pharmacol. 2022;13:1062408.CrossRefPubMedPubMedCentral Matthews PC, Campbell C, Sandulescu O, Maticic M, Ruta SM, Rivero-Juarez A, van Welzen BJ, Tan BK, Garcia F, Gherlan GS, et al. Acute severe hepatitis outbreak in children: a perfect storm. What do we know, and what questions remain? Front Pharmacol. 2022;13:1062408.CrossRefPubMedPubMedCentral
32.
go back to reference Gates S, Andreani J, Dewar R, Smith DB, Templeton K, Child HT, Breuer J, Golubchik T, Bassano I, Wade MJ, et al. Postpandemic rebound of adeno-associated virus type 2 (AAV2) infections temporally associated with an outbreak of unexplained severe acute hepatitis in children in the United Kingdom. J Med Virol. 2023;95:e28921.CrossRefPubMed Gates S, Andreani J, Dewar R, Smith DB, Templeton K, Child HT, Breuer J, Golubchik T, Bassano I, Wade MJ, et al. Postpandemic rebound of adeno-associated virus type 2 (AAV2) infections temporally associated with an outbreak of unexplained severe acute hepatitis in children in the United Kingdom. J Med Virol. 2023;95:e28921.CrossRefPubMed
Metadata
Title
A dual role for adeno-associated virus in human health
Author
Natalia M Araujo
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02196-8

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.